ABSTRACT:(؉)-1,4-Dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595 or AG-7352) is currently under investigation for the treatment of platinum-resistant ovarian cancer and acute myeloid leukemia. In vitro voreloxin undergoes minimal cytochrome P450 (P450) and UDP glucuronosyltransferase (UGT)-mediated metabolism, and in vivo excretion of unchanged voreloxin as the major species is consistent with the slow rate of metabolism observed in vitro. The objective of the present study was to examine the cross-species metabolic profile of voreloxin and to identify and characterize the metabolites formed in rats. We also investigated baculovirus-expressed human P450s and UGTs to determine which isoforms participated in voreloxin metabolism. Incubations using human, monkey, and rat liver microsomes showed monkey and rat metabolism is similar to human. Voreloxin and metabolites collected from plasma, bile, and urine from rats administered radiolabeled voreloxin were separated by high-performance liquid chromatography, and their structures were elucidated by liquid chromatography/tandem mass spectrometry. Activity of metabolites was determined with authentic reference standards in cellbased cytotoxicity assays. The proposed structures of metabolites suggest that metabolic pathways for voreloxin include glucuronide conjugation, oxidation, N-dealkylation, and O-dealkylation.Voreloxin is a replication-dependent DNA-damaging agent that intercalates DNA and inhibits topoisomerase II, resulting in doublestranded DNA breaks, irreversible G2 arrest, and rapid apoptosis. The topoisomerase II-associated DNA intercalation and DNA damage produced by voreloxin are highly selective and show selectivity for proliferating cells. These targeted DNA-protein interactions may contribute to the broad clinical responses observed with voreloxin to date. The inhibition of topoisomerase II by voreloxin is differentiable from the actions of classic topoisomerase inhibitors, including etoposide, doxorubicin, and topotecan (Stockett et al., 2008). Voreloxin is a naphthyridine-derived small molecule that exists as a zwitterioncontaining carboxylic acid and amine functional groups (Fig. 1). Voreloxin is currently under clinical investigation in acute myeloid leukemia and ovarian cancer (Burris et al., 2007;Lancet et al., 2007).Preclinical pharmacokinetic studies in rats and monkeys showed that voreloxin has dose-proportional exposure, low to moderate clearance, a moderate half-life, and low interindividual variability. In humans, pharmacokinetic estimates show dose linear increase in exposure, low clearance, and a long half-life (Hoch and Silverman, 2007). In vitro studies using rat, monkey, and human liver microsomes indicated that voreloxin undergoes minimal oxidative and conjugative metabolism (Hoch et al., 2005). In addition, in vitro profiling suggests that rat metabolism is a good model of voreloxin human metabolism. In mass balance studies, greater than 90...